58 completed, 4 terminated, 1 recruiting, 1 unknown. 32 Phase 1, 14 Phase 3, 12 Phase 2, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 32 | Completed 31, Terminated 1 |
| Phase 3 | 14 | Completed 11, Terminated 2, Withdrawn 1 |
| Phase 2 | 12 | Completed 11, Terminated 1 |
| Phase 4 | 2 | Completed 2 |
Follow eslicarbazepine acetate: new trials by email Literature Review of eslicarbazepine acetate trials Research Report on eslicarbazepine acetate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prospective Study of Eslicarbazepine in Adults With Focal-Onset Seizures Eslicarbazepine acetate - Focal-Onset Seizures | Recruiting | King Edward Medical University | 1500 | 2025-12-02 | 2026-09-09 | |
| Clinical Trial for Zebinix (Eslicarbazepine Acetate) in Healthy Korean and Caucasian Adult Zebinix 400mg, Placebo for Zebinix 400mg, Zebinix 800mg - Partial-onset Seizures With or Without Secondary Generalisation | Phase 1 | Completed | Whanin Pharmaceutical Company | 50 | 2019-08-22 | 2020-01-07 |
| Anti-epileptogenic Effects of Eslicarbazepine Acetate ESL 800 mg, Placebo - Post Stroke Epilepsy | Phase 2 | Completed | Bial - Portela C S.A. | 129 | 2019-05-29 | 2025-05-02 |
| ZEBinix® Retention Rate in Epilepsy in Elderly Patients Zebinix - Epilepsy, Aging Disorder | Unknown | Centre Hospitalier Saint Joseph Saint Luc de Lyon | 50 | 2019-04-01 | 2020-01-09 | |
| A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures Eslicarbazepine acetate, Eslicarbazepine Acetate - Epilepsy With Partial On-set Seizures | Phase 4 | Completed | Sumitomo Pharma America, Inc. | 102 | 2017-07-07 | 2020-06-16 |
| A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug Eslicarbazepine acetate - Epilepsy | Phase 3 | Withdrawn | Sumitomo Pharma America, Inc. | 2017-07-06 | 2018-01-16 | |
| Bioequivalence of Two Different Sources of Eslicarbazepine Acetate Eslicarbazepine acetate (ESL) - Epilepsy | Phase 1 | Completed | Bial - Portela C S.A. | 24 | 2016-12-03 | 2017-04-17 |
| Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults Eslicarbazepine, Carbamazepine - Epilepsy | Phase 4 | Completed | Stanford University | 46 | 2016-07-01 | 2019-06-04 |
| Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures ESL 800 mg, ESL 1200 mg, ESL 1600 mg - Epilepsy | Phase 3 | Completed | Bial - Portela C S.A. | 206 | 2016-03-01 | 2018-10-16 |
| Double-blind Study in Paediatric Epileptic to Compare the Subject Preference for ESL Suspension Formulation With Alternative Flavours ESL Banana taste, ESL Grape taste, ESL Tutti-Frutti taste - Epilepsy | Phase 2 | Completed | Bial - Portela C S.A. | 38 | 2012-12-01 | 2014-04-03 |
| A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS) Eslicarbazepine Acetate tablets - Partial Onset Seizures | Completed | Eisai Inc. | 254 | 2012-04-01 | 2015-08-19 | |
| Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA) ESL - Epilepsy | Completed | Bial - Portela C S.A. | 56 | 2012-03-01 | 2017-01-06 | |
| Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures Eslicarbazepine acetate (BIA 2-093) - Epilepsy | Phase 3 | Completed | Bial - Portela C S.A. | 815 | 2010-12-01 | 2016-09-29 |
| Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain Eslicarbazepine acetate (BIA 2-093), Placebo - Painful Diabetic Neuropathy | Phase 3 | Terminated | Bial - Portela C S.A. | 332 | 2010-11-01 | 2014-07-18 |
| Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate BIA 2-093 - Epilepsy | Phase 1 | Completed | Bial - Portela C S.A. | 40 | 2010-10-01 | 2015-01-12 |
| Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia Eslicarbazepine acetate (BIA 2-093), Placebo - Post Herpetic Neuralgia | Phase 3 | Terminated | Bial - Portela C S.A. | 240 | 2010-09-01 | 2014-04-07 |
| Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy retigabine/ezogabine, lacosamide, zonisamide - Epilepsy | Completed | GlaxoSmithKline | 6498 | 2010-09-01 | 2013-09-16 | |
| Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures Eslicarbazepine acetate (BIA 2-093), Placebo - Partial Epilepsy | Phase 2 | Completed | Bial - Portela C S.A. | 123 | 2010-08-01 | 2014-10-24 |
| Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic Eslicarbazepine acetate 1600 mg, Eslicarbazepine acetate 1200 mg - Epilepsy | Phase 3 | Completed | Sumitomo Pharma America, Inc. | 172 | 2010-06-01 | 2016-10-24 |
| Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients Eslicarbazepine Acetate - Epilepsy | Phase 3 | Completed | Bial - Portela C S.A. | 72 | 2010-04-01 | 2017-08-07 |
Showing 20 of 65. Sign in to see all of them.
Epilepsy (51) · Epilepsies, Partial (9) · Seizures (6) · Diabetic Neuropathies (2) · Neuralgia, Postherpetic (2) · Fibromyalgia (1) · Migraine Disorders (1) · Neuralgia (1)
Bial - Portela C S.A. (54) · Sumitomo Pharma America, Inc. (5) · Centre Hospitalier Saint Joseph Saint Luc de Lyon (1) · Eisai Inc. (1) · GlaxoSmithKline (1) · King Edward Medical University (1) · Stanford University (1) · Whanin Pharmaceutical Company (1)
Portugal (20) · United States (9) · Germany (8) · France (7) · Czechia (5) · United Kingdom (5) · Canada (4) · Italy (4) · Poland (4) · Romania (4) · Ukraine (4) · Austria (3) · Bulgaria (3) · Serbia (3) · Spain (3)
Manuel Vaz-da-Silva, MD, PhD (3) · Manuel Vaz da Silva, MD, PhD (2) · Patricio Soares-da-Silva, MD, PhD (2) · Alberto Alain Gabbai, MD (1) · Antonio Gil-Nagel, MD (1) · Elinor Ben-Menachem, MD (1) · Eugen Trinka, MD MSc FRCP (1) · In-Jin Jang, MD, PhD (1) · Jose Lopes-Lima, MD (1)
PMID 33338829, PMID 31878820, PMID 19356391, PMID 32801102, PMID 37675038
2008 (1), 2009 (1), 2018 (1)